General
Preferred name
FROVATRIPTAN
Synonyms
SB-209509AX ()
FROVELAN ()
FROVA ()
Frovatriptan (succinate hydrate) ()
(R)-Frovatriptan (succinate hydrate) ()
SB 209509 (succinate hydrate) ()
VML 251 (succinate hydrate) ()
SB 209509 Succinate,VML 251 Succinate ()
Frovatriptan succinate hydrate ()
FROVATRIPTAN SUCCINATE ()
Migard ()
Mylatrip ()
Allergo filmtabletten ()
SB 209509 AX ()
VML 251 ()
Frovatriptan succinate monohydrate ()
VML-251 ()
SB-209509-AX ()
NSC-760422 ()
SB 209509-AX ()
MIGUARD ()
FROVATRIPTAN SUCCINATE MONOHYDRATE ()
P&D ID
PD009599
CAS
158930-09-7
158930-17-7
158747-02-5
Tags
available
drug
Approved by
FDA
First approval
2001
Drug indication
Migraine
Pain
migraine disorder
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Frovatriptan is a triptan (tryptamine-based) drug. (GtoPdb)
DESCRIPTION Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate hydrate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and ¦Á1-adrenoceptor. Frovatriptan succinate hydrate has the potential for migraine research[1][2].
PRICE 64
DESCRIPTION Frovatriptan succinate hydrate (Frova) is effective in treating the full spectrum of migraine including the associated symptoms of nausea, vomiting, photophobia, and phonophobia. Frovatriptan succinate hydrate can also be used as in mini-prophylaxis in menstrual migraine.?Frovatriptan succinate hydrate is a potent, high affinity, selective and orally active 5-HT1B, HT1D receptor agonist and a moderately potent 5-HT7 receptor agonist, with pKi values of 8.6, 8.4, and 6.7, respectively.
DESCRIPTION Frovatriptan is a selective agonist of the 5-HT1B and 5-HT1D (Kis = 2.51 and 3.98 nM, respectively). (BOC Sciences Bioactive Compounds)
DESCRIPTION Frovatriptan succinate hydrate (Frova) is effective in treating the full spectrum of migraine including the associated symptoms of nausea, vomiting, photophobia, and phonophobia. Frovatriptan succinate hydrate can also be used as in mini-prophylaxis in menstrual migraine. Frovatriptan succinate hydrate is a potent, high affinity, selective and orally active 5-HT1B, HT1D receptor agonist and a moderately potent 5-HT7 receptor agonist, with pKi values of 8.6, 8.4, and 6.7, respectively. (TargetMol Bioactive Compound Library)
Compound Sets
23
BOC Sciences Bioactive Compounds
frova-cas-158930-17-7-item-387521
Cayman Chemical Bioactives
23771
ChEMBL Approved Drugs
CHEMBL1279
CHEMBL2138684
ChEMBL Drugs
CHEMBL1279
CHEMBL2138684
Concise Guide to Pharmacology 2017/18
7191
Concise Guide to Pharmacology 2019/20
7191
Concise Guide to Pharmacology 2021/22
7191
Concise Guide to Pharmacology 2023/24
7191
Drug Repurposing Hub
DrugBank
DB00998
DrugBank Approved Drugs
DB00998
DrugCentral
1251
DrugCentral Approved Drugs
1251
DrugMAP
DM7RE8P
DrugMAP Approved Drugs
DM7RE8P
EUbOPEN Chemogenomics Library
EUB0000942
Guide to Pharmacology
7191
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1279
MedChem Express Bioactive Compound Library
HY-B1658A
NCATS Inxight Approved Drugs
H82Q2D5WA7
NPC Screening Collection
Selleckchem Bioactive Compound Library
frovatriptan-succinate
TargetMol Bioactive Compound Library
T11326
External IDs
65
Properties
(calculated by RDKit )
Molecular Weight
243.14
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
1.34
TPSA
70.91
Fraction CSP3
0.36
Chiral centers
1.0
Largest ring
6.0
QED
0.74
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
5-HT1B
5-HT1D
Human 5-HT7 Receptor
HTR1A, HTR1B, HTR1D
5-HT Receptor
Indication
migraine headache
MOA
serotonin receptor agonist
Therapeutic Class
Antimigraine Agents
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Recommended Cell Concentration
100 nM
Source data